Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Clinical Study
Gastroenterology Research and Practice
Volume 2018 (2018), Article ID 8046838, 2 pages
https://doi.org/10.1155/2018/8046838
Letter to the Editor

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

1Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
2Department of Gastroenterology, Institute for Adult Disease, Asahi Life Foundation, Tokyo, Japan
3Advanced Medical Research Center, Yokohama City University, Yokohama, Japan

Correspondence should be addressed to Masaaki Kondo; pj.ca.uc-amahokoy@uodnokm

Received 17 January 2018; Accepted 20 February 2018; Published 22 March 2018

Academic Editor: Tatsuya Toyokawa

Copyright © 2018 Soichiro Sue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Kashani and A. T. B. Abadi, “Comment on “first-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin”,” Gastroenterology Research and Practice, vol. 2018, Article ID 5173904, 3 pages, 2018. View at Publisher · View at Google Scholar
  2. S. Sue, N. Suzuki, W. Shibata et al., “First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin,” Gastroenterology Research and Practice, vol. 2017, Article ID 2019802, 6 pages, 2017. View at Publisher · View at Google Scholar
  3. S. Sue, H. Kuwashima, Y. Iwata et al., “The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication,” Internal Medicine, vol. 56, no. 11, pp. 1277–1285, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Kawai, T. Yamagishi, K. Yagi et al., “Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities,” Journal of Gastroenterology and Hepatology, vol. 23, Supplement 2, pp. S171–S174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ono, M. Kato, S. Nakagawa, K. Mabe, and N. Sakamoto, “Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin,” Helicobacter, vol. 22, no. 3, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Suzuki, K. Matsuo, H. Ito et al., “Smoking increases the treatment failure for Helicobacter pylori eradication,” The American Journal of Medicine, vol. 119, no. 3, pp. 217–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Q. Dong, T. P. Singh, X. Wei, H. Yao, and H. L. Wang, “Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion?” Helicobacter, vol. 22, no. 6, article e12438, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sue, M. Ogushi, I. Arima et al., “Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial,” Helicobacter, vol. 21, 2017. View at Google Scholar